SCHEMBL13033200

SCHEMBL13033200

CC1CN(CC(O)COc2cccc(N(C)C)c2)CC(C)O1

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 5/20 0.61
MAPK1 P28482 3/20 0.58
ALDH1A1 P00352 4/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
KDM4E B2RXH2 2/20 0.53
POLB P06746 1/20 0.53
GAA P10253 2/20 0.51
TSHR P16473 1/20 0.51
USP2 O75604 1/20 0.49
ACE2 Q9BYF1 1/20 0.49
PRMT5 O14744 1/20 0.48
WDR77 Q9BQA1 1/20 0.48
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47
THRB P10828 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13033140 0.85 L3MBTL1 (0.65) L3MBTL1MAPK1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL13033214 0.84 USP2 (0.69) L3MBTL1MAPK1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL13033173 0.83 MAPK1 (0.78) L3MBTL1MAPK1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL13033218 0.81 L3MBTL1 (0.60) L3MBTL1MAPK1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL13033233 0.79 L3MBTL1 (0.72) L3MBTL1MAPK1SMN1; SMN2GAATSHR
SCHEMBL21202616 0.77 L3MBTL1 (0.79) L3MBTL1MAPK1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL13033213 0.77 L3MBTL1 (0.97) L3MBTL1MAPK1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL13033210 0.76 L3MBTL1 (0.65) L3MBTL1MAPK1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL13033211 0.76 MAPK1 (0.77) L3MBTL1MAPK1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL13033217 0.76 PRMT5 (0.80) PRMT5WDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11661580-B2 Method of inhibiting tau phosphorylation CASSAVA SCIENCES, INC. (US) 2023-05-30 US disclosed
US-11661580-B2 Method of inhibiting tau phosphorylation CASSAVA SCIENCES, INC. (US) 2023-05-30 US disclosed
US-11385221-B2 Alzheimer's disease assay in a living patient PAIN THERAPEUTICS, INC. (US) 2022-07-12 US disclosed
US-20210389298-A1 Alzheimer's Disease Assay in a Living Patient PAIN THERAPEUTICS, INC. (US) 2021-12-16 US disclosed
US-20210095248-A1 METHOD OF INHIBITING TAU PHOSPHORYLATION PAIN THERAPEUTICS, INC. 2021-04-01 US disclosed
EP-3791875-A1 METHOD FOR INHIBITING GROWTH OF CANCER CELLS Pain Therapeutics, Inc. (US) 2021-03-17 EP disclosed
US-10760052-B2 Method of inhibiting tau phosphorylation Cassava Science, Inc. (US) 2020-09-01 US disclosed
US-20190271686-A1 ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT PAIN THERAPEUTICS, INC. 2019-09-05 US disclosed
US-10363239-B2 Method for inhibiting growth of cancer cells PAIN THERAPEUTICS (US) 2019-07-30 US disclosed
US-20190136184-A1 METHOD OF INHIBITING TAU PHOSPHORYLATION CASSAVA SCIENCES, INC. 2019-05-09 US disclosed
US-20140018341-A1 METHOD OF INHIBITING TAU PHOSPHORYLATION CASSAVA SCIENCES, INC. 2014-01-16 US disclosed
WO-2014012054-A1 ALZHEIMER'S DISEASE ASSAY IN A LIVING PATENT PAIN THERAPEUTICS, INC. (US) 2014-01-16 WO disclosed
WO-2014011917-A2 A METHOD OF INHIBITING TAU PHOSPHORYLATION PAIN THERAPEUTICS, INC. (US) 2014-01-16 WO disclosed
US-20140017698-A1 ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT WANG HOAU-YAN (US) 2014-01-16 US disclosed
US-20140018341-A1 METHOD OF INHIBITING TAU PHOSPHORYLATION CASSAVA SCIENCES, INC. 2014-01-16 US disclosed
US-20140017699-A1 ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT CASSAVA SCIENCES, INC. 2014-01-16 US disclosed
US-20100279996-A1 NOVEL ANALGESIC THAT BINDS FILAMIN A BARBIER LINDSAY BURNS 2010-11-04 US disclosed
US-20100279997-A1 ANALGESIC THAT BINDS FILAMIN A PAIN THERAPEUTICS 2010-11-04 US disclosed
US-20100279996-A1 NOVEL ANALGESIC THAT BINDS FILAMIN A BARBIER LINDSAY BURNS 2010-11-04 US disclosed
WO-2010051374-A1 ANALGESIC THAT BINDS FILAMIN A PAIN THERAPEUTICS, INC. (US) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10363239-B2 Method for inhibiting growth of cancer cells FLNA, FLNB, FSCN1 L3MBTL1 1041/4885MAPK1 10/4885ALDH1A1 3552/4885
US-20190136184-A1 METHOD OF INHIBITING TAU PHOSPHORYLATION FLNA, FLNB, MAPT L3MBTL1 1789/4885MAPK1 45/4885ALDH1A1 4388/4885
US-10760052-B2 Method of inhibiting tau phosphorylation FLNA, FLNB, MAPT L3MBTL1 1789/4885MAPK1 45/4885ALDH1A1 4388/4885
US-20100279996-A1 NOVEL ANALGESIC THAT BINDS FILAMIN A FLNA, OPRL1, FLNB L3MBTL1 2524/4885MAPK1 3237/4885ALDH1A1 1291/4885
US-20140018341-A1 METHOD OF INHIBITING TAU PHOSPHORYLATION FLNA, FLNB, MAPT L3MBTL1 1789/4885MAPK1 45/4885ALDH1A1 4388/4885
US-20210095248-A1 METHOD OF INHIBITING TAU PHOSPHORYLATION FLNA, FLNB, MAPT L3MBTL1 1789/4885MAPK1 45/4885ALDH1A1 4388/4885
US-11661580-B2 Method of inhibiting tau phosphorylation FLNA, FLNB, MAPT L3MBTL1 1789/4885MAPK1 45/4885ALDH1A1 4388/4885
US-20100279997-A1 ANALGESIC THAT BINDS FILAMIN A FLNA, FLNB, OPRL1 L3MBTL1 1166/4885MAPK1 2746/4885ALDH1A1 1476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.